Glycosaminoglycans from <i>Litopenaeus vannamei</i> Inhibit the Alzheimer’s Disease β Secretase, BACE1

Glycosaminoglycans from <i>Litopenaeus vannamei</i> Inhibit the Alzheimer’s Disease β Secretase, BACE1

Only palliative therapeutic options exist for the treatment of Alzheimer’s Disease; no new successful drug candidates have been developed in over 15 years. The widely used clinical anticoagulant heparin has been reported to exert beneficial effects through multiple pathophysiological pathways involv...

Full description

Bibliographic Details
Main Authors: Courtney J. Mycroft-West, Anthony J. Devlin, Lynsay C. Cooper, Scott E. Guimond, Patricia Procter, Marco Guerrini, Gavin J. Miller, David G. Fernig, Edwin A. Yates, Marcelo A. Lima, Mark A. Skidmore
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Marine Drugs
Subjects:
Alzheimer’s disease
amyloid-β
BACE1
β-secretase
glycosaminoglycan
chondroitin sulfate
Online Access:https://www.mdpi.com/1660-3397/19/4/203

Internet

https://www.mdpi.com/1660-3397/19/4/203

Similar Items